Results 241 to 250 of about 76,403 (315)

LncRNA H19‐Encoded Micropeptide altH19 Promotes DNA Replication and Mitosis in Myeloma Cells by Enhancing the Phosphorylation of CDK2 at Threonine 160

Cell Proliferation, EarlyView.
The micropeptide altH19 interacts with phosphorylated CDK2 (p‐CDK2), subsequently activating CDK2 phosphorylation. This enhances the downstream E2F1 target gene RB activity, which accelerates DNA replication, ultimately leading to rapid myeloma cell mitosis and proliferation.
Yaxin Zhang, Wenjing Li, Xu Cao, Jiwei Mao, Xiaodan Zhou, Linlin Liu, Ruosi Yao   +6 more
wiley   +1 more source

Cholesterol metabolism reprogramming in multiple myeloma: examining its specificity and impact on the immune microenvironment. [PDF]

Am J Cancer Res
Teng H, Wang F, Liu H, Zhang X.
europepmc   +1 more source

Cyclophosphamide—A promising solution for refractory ICANS

British Journal of Haematology, EarlyView.
Manan Vora, Himanshu Gujarathi, Hasmukh Jain, Alok Shetty, Vasundhara Patil, Savan Pandey, M. V. Ramya Kumar, Lingaraj Nayak   +7 more
wiley   +1 more source

Homoharringtonine Promotes FTO Degradation to Suppress LILRB4‐Mediated Immune Evasion in Acute Monocytic Leukaemia

Cell Proliferation, EarlyView.
Homoharringtonine (HHT) suppresses immune evasion in acute monocytic leukaemia (AML‐M5) by attenuating the FTO/m6A/LILRB4 axis, thereby enhancing CD8+ T cell cytotoxicity. ABSTRACT Acute monocytic leukaemia, a subtype of acute myeloid leukaemia (AML), is a highly aggressive malignancy characterised by a poor prognosis, primarily due to the ability of ...
Fangfang Huang, Xiang Luo, Mengyu Zhang, Le Jin, Wenxin Sun, Peihan Chen, Xiuli Hong, Chenyu Xu, Meizhi Jiang, Die Hu, Bin Zhang, Shengwei Hu, Chuanjiang Yang, Rui Gao, Jinzhang Zeng, Quanyi Lu, Qiang Luo, Jun Wu, Siming Chen   +18 more
wiley   +1 more source

Selinexor's Immunomodulatory Impact in Advancing Multiple Myeloma Treatment. [PDF]

Cells
Tasbihi K, Bruns H.
europepmc   +1 more source

Reversal of MPPa‐PDT Resistance in Osteosarcoma by Targeting ROCK2‐Mediated Autophagy

Cell Proliferation, EarlyView.
ROCK2 competes with MST1 to bind to the aa 28‐198 region of SAV1 and then regulates the Hippo pathway to affect autophagy, resulting in the resistance of OS to MPPa‐PDT. Targeted inhibition of ROCK2 by screening for J059‐0149 increases the sensitivity of osteosarcoma to MPPa‐PDT. ABSTRACT Osteosarcoma (OS) is a primary bone tumour that occurs mostly in
Xuan Yi, Xueqiang Deng, Jianyong Deng, Chen Li, Hong Peng, Yunyan Du, Qing Li, Xiaohua Yan, Xin Hu, Yan Zheng, Shenliang Chen, Ting Xiong, Debin Xu, Leifeng Chen, Liang Hao   +14 more
wiley   +1 more source

Resistance Mechanisms to BCMA Targeting Bispecific Antibodies and CAR T-Cell Therapies in Multiple Myeloma. [PDF]

Cells
Tedder B, Bhutani M.
europepmc   +1 more source

European Expert Panel Consensus on Outpatient Administration of Teclistamab and Talquetamab in Patients With Multiple Myeloma: Feasibility, Key Considerations, and Future Directions

European Journal of Haematology, EarlyView.
ABSTRACT Objectives Teclistamab and talquetamab treatments are typically initiated in a hospital due to the potential risk of cytokine release syndrome. However, emerging data support the potential for outpatient administration (i.e., administration without overnight hospital admission).
Thomas Lund, Cyrus Khandanpour, Sébastien Anguille, Jens Kisro, Maria Theresa Krauth, Johan Lund, Inger Nijhof, Enrique M. Ocio, Elena Zamagni, Matthieu Javelot, Claire Albrecht, Cristina Entrala Cerezo, Aurore Perrot   +12 more
wiley   +1 more source

Chemotherapy-Mediated Induction of PD-L1 via SEI1 Facilitates Myeloma Immune Evasion. [PDF]

Adv Sci (Weinh)
Chen R, Li Z, Fang Z, Li Z, Yang D, Li Y, Liu S, Liu Z, Liu R, Liu H.   +9 more
europepmc   +1 more source

Vaccination in Multiple Myeloma: Challenges and Strategies

European Journal of Haematology, EarlyView.
ABSTRACT Background Multiple myeloma (MM) is a hematological malignancy characterized by profound immunosuppression resulting from both disease‐related mechanisms and treatment‐induced immune dysfunction. This compromised immune status markedly increases susceptibility to infections, a leading cause of morbidity and mortality in MM patients.
Enrica Antonia Martino, Ernesto Vigna, Antonella Bruzzese, Nicola Amodio, Eugenio Lucia, Virginia Olivito, Caterina Labanca, Santino Caserta, Francesco Mendicino, Fortunato Morabito, Massimo Gentile   +10 more
wiley   +1 more source